semaglutide for parkinson's Focus: After weight loss, Alzheimer's may be next frontier drugs like Ozempic Weight-loss drug semaglutide does not

K252a, a high-affinity nerve growth factor receptor blocker, improves psoriasis: an in vivo study using the severe combined immunodeficient mouse-human skin model

NEJM, 2016

Active Whole Spectrum Difference Our Active Whole Spectrum extracts contain a full profile of naturally occurring constituents and are extracted without the use of toxic solvents and/or harsh chemicals

379 Current researches have demonstrated that the mechanisms of systemic IR and brain-specific IR have close links with AD pathogenesis

Phase Weeks 1-2 Draw volume 7.5 units (0.075 mL) Total blend delivered ~2.0 mg total blend GHK-Cu ~1.25 mg KPV ~250 mcg BPC-157 ~250 mcg TB-500 ~250 mcg Phase Weeks 3-4 Draw volume 15 units (0.15 mL) Total blend delivered ~4.0 mg total blend GHK-Cu ~2.5 mg KPV ~500 mcg BPC-157 ~500 mcg TB-500 ~500 mcg Phase Weeks 5-8 Draw volume 22.5 units (0.225 mL) Total blend delivered ~6.0 mg total blend GHK-Cu ~3.75 mg KPV ~750 mcg BPC-157 ~750 mcg TB-500 ~750 mcg Phase Weeks 9-12 (taper) Draw volume 15 units (0.15 mL) Total blend delivered ~4.0 mg total blend GHK-Cu ~2.5 mg KPV ~500 mcg BPC-157 ~500 mcg TB-500 ~500 mcg Blend ratio 50 / 10 / 10 / 10 mg GHK-Cu dominant Select a draw volume from the titration table above to see the approximate amount of each peptide delivered